MX337775B - Composiciones de bepotastina. - Google Patents

Composiciones de bepotastina.

Info

Publication number
MX337775B
MX337775B MX2013007409A MX2013007409A MX337775B MX 337775 B MX337775 B MX 337775B MX 2013007409 A MX2013007409 A MX 2013007409A MX 2013007409 A MX2013007409 A MX 2013007409A MX 337775 B MX337775 B MX 337775B
Authority
MX
Mexico
Prior art keywords
compositions including
bepotastine
compositions
bepotastine compositions
corticosteroid
Prior art date
Application number
MX2013007409A
Other languages
English (en)
Other versions
MX2013007409A (es
Inventor
Angel Padilla
George Baklayan
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2013007409A publication Critical patent/MX2013007409A/es
Publication of MX337775B publication Critical patent/MX337775B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composiciones novedosas que incluyen besilato de bepotastina y un corticoesteroide, composiciones que incluyen al menos aproximadamente 0.008 % p/v de cloruro de benzalconio, y composiciones que incluyen hidroxipropilmetil celulosa E15 LV.
MX2013007409A 2011-01-04 2012-01-03 Composiciones de bepotastina. MX337775B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161429721P 2011-01-04 2011-01-04
PCT/US2012/020028 WO2012094283A2 (en) 2011-01-04 2012-01-03 Bepotastine compositions

Publications (2)

Publication Number Publication Date
MX2013007409A MX2013007409A (es) 2013-11-01
MX337775B true MX337775B (es) 2016-03-18

Family

ID=46457931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007409A MX337775B (es) 2011-01-04 2012-01-03 Composiciones de bepotastina.

Country Status (12)

Country Link
US (2) US20120323178A1 (es)
EP (1) EP2736491B1 (es)
JP (1) JP5683719B2 (es)
KR (1) KR101546596B1 (es)
CN (1) CN103269687B (es)
AU (1) AU2012204557B2 (es)
BR (1) BR112013017183A2 (es)
CA (1) CA2822683C (es)
ES (1) ES2626134T3 (es)
MX (1) MX337775B (es)
PL (1) PL2736491T3 (es)
WO (1) WO2012094283A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048059A2 (en) * 2010-10-06 2012-04-12 Ista Pharmaceuticals, Inc. Bepotastine compositions
MX361886B (es) 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
ES2920802T3 (es) * 2013-03-26 2022-08-09 Optinose As Administración nasal
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
HRP20211515T1 (hr) * 2013-09-13 2021-12-24 Glenmark Specialty S.A. Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN103816121B (zh) * 2014-03-07 2016-01-20 上海现代药物制剂工程研究中心有限公司 苯磺酸贝他斯汀鼻腔喷雾剂及其制备方法
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
WO2015183047A1 (ko) * 2014-05-30 2015-12-03 동아에스티 주식회사 베포타스틴과 글리세릴베헤네이트를 포함하는 약제학적 제제
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US9119876B1 (en) 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
JP7106852B2 (ja) * 2016-12-20 2022-07-27 大正製薬株式会社 懸濁型外用液剤
AU2018325461B2 (en) * 2017-09-02 2020-06-11 Iview Therapeutics, Inc. In situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
BR112020016817A2 (pt) * 2018-02-23 2020-12-15 Glenmark Specialty S.A. Método para tratar sintomas associados à rinite alérgica, método para fornecer um início de ação mais rápido para alívio da rinite alérgica e método para tratar um sujeito humano pediátrico que sofre de rinite alérgica
WO2019183416A1 (en) 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
US12102645B2 (en) 2018-06-08 2024-10-01 Toko Yakuhin Kogyo Co., Ltd. Fluticasone furoate nasal preparation composition
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
US20210283074A1 (en) * 2020-03-16 2021-09-16 Nasus Pharma Ltd. Polymeric Compositions for Intranasal Administration
IL301496A (en) * 2020-09-24 2023-05-01 Nflection Therapeutics Inc Treatment of impaired cognitive function with pyrrolpyridine-anil compounds
CN117954002B (zh) * 2024-01-05 2024-10-22 苏州腾迈医药科技有限公司 分子对关系的展示方法及装置、介质

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8902300D0 (en) 1989-02-02 1989-03-22 Bryce Smith Derek Antirhinoviral preparations
CN1222852A (zh) * 1996-06-04 1999-07-14 普罗克特和甘保尔公司 含鼻内类固醇和抗组胺剂的鼻喷雾剂
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
TW486475B (en) 1996-12-26 2002-05-11 Ube Industries Acid addition salt of optically active piperidine compound and process for preparing the same
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
SK14762003A3 (sk) * 2001-05-31 2004-08-03 Pharmacia Corporation Kožou prestupujúci prípravok obsahujúci selektívne inhibujúcu cyklooxygenázu-2 a jednosýtny alkohol
ES2258175T3 (es) * 2001-12-05 2006-08-16 Alcon, Inc. Utilizacion de un antagonista de h1 y remixolona como esteroide inofensivo para el tratamiento de la rinitis.
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
EP1525884B1 (en) * 2002-07-31 2011-10-12 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
PT1545548E (pt) * 2002-08-30 2010-09-02 Nycomed Gmbh Utilização da combinação de ciclesonida e anti-histamínicos para o tratamento de rinite alérgica
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
MXPA06003320A (es) * 2003-09-24 2006-06-08 Combinatorx Inc Regimenes terapeuticos para administrar combinaciones de farmacos.
EP1631315B1 (en) * 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
ES2704482T3 (es) * 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
SI1919450T1 (sl) * 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
US20090325917A1 (en) * 2006-10-19 2009-12-31 Cipla Limited Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
KR100878698B1 (ko) 2007-04-05 2009-01-13 한미약품 주식회사 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
WO2008127975A2 (en) 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
KR20090061972A (ko) 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
JP2012501315A (ja) * 2008-09-02 2012-01-19 グラクソ グループ リミテッド 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８
JP2010195716A (ja) 2009-02-25 2010-09-09 Takeda Chem Ind Ltd 点鼻睡眠導入剤
WO2012048059A2 (en) * 2010-10-06 2012-04-12 Ista Pharmaceuticals, Inc. Bepotastine compositions

Also Published As

Publication number Publication date
PL2736491T3 (pl) 2017-09-29
KR20130135296A (ko) 2013-12-10
US10736841B2 (en) 2020-08-11
EP2736491A4 (en) 2014-07-09
CA2822683C (en) 2015-05-12
EP2736491A2 (en) 2014-06-04
BR112013017183A2 (pt) 2017-07-25
AU2012204557A1 (en) 2013-05-02
WO2012094283A2 (en) 2012-07-12
US20120255544A1 (en) 2012-10-11
CN103269687A (zh) 2013-08-28
US20120323178A1 (en) 2012-12-20
CA2822683A1 (en) 2012-07-12
KR101546596B1 (ko) 2015-08-21
WO2012094283A3 (en) 2012-10-26
EP2736491B1 (en) 2017-04-05
AU2012204557B2 (en) 2015-05-14
CN103269687B (zh) 2016-09-14
JP2014501779A (ja) 2014-01-23
MX2013007409A (es) 2013-11-01
ES2626134T3 (es) 2017-07-24
JP5683719B2 (ja) 2015-03-11

Similar Documents

Publication Publication Date Title
MX2013007409A (es) Composiciones de bepotastina.
MX2013003152A (es) Composiciones de bepotastina.
IN2015DN01480A (es)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
ECSP14011359A (es) Inhibidores de bromodominios
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
MX361499B (es) Baricitinib deuterado.
MX2015001246A (es) Ibrutinib deuterado.
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MY194495A (en) Compositions and methods for transmucosal absorption
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
IN2014DN06869A (es)
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
GB201101517D0 (en) Receptor antagonists
IN2014DN09347A (es)
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
MX356801B (es) Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
PH12015501146A1 (en) Hydantoin derivative
MX2010005105A (es) Ciclopentanos substituidos que comprenden actividad de prostaglandina.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.

Legal Events

Date Code Title Description
FG Grant or registration